;PMID: 8424894
;source_file_990.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..48] = [t:0..48]
;1)sentence:[e:54..194] = [t:54..194]
;2)section:[e:198..240] = [t:198..240]
;3)section:[e:244..318] = [t:244..318]
;4)sentence:[e:322..400] = [t:322..400]
;5)sentence:[e:402..574] = [t:402..574]
;6)sentence:[e:575..631] = [t:575..631]
;7)sentence:[e:633..716] = [t:633..716]
;8)sentence:[e:717..963] = [t:717..963]
;9)sentence:[e:964..1057] = [t:964..1057]
;10)sentence:[e:1058..1164] = [t:1058..1164]
;11)sentence:[e:1165..1255] = [t:1165..1255]
;12)sentence:[e:1257..1491] = [t:1257..1491]
;13)sentence:[e:1493..1604] = [t:1493..1604]
;14)sentence:[e:1605..1702] = [t:1605..1702]
;15)sentence:[e:1703..1831] = [t:1703..1831]
;16)section:[e:1835..1879] = [t:1835..1879]

;section 0 Span:0..48
;J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Steroid) (NNP:[10..17] Biochem)
        (NNP:[18..21] Mol) (NNP:[22..26] Biol) (.:[26..27] .) (CD:[28..32] 1993)
        (CC:[33..40] Jan;44-LRB-) (CD:[40..41] 1) (-RRB-:[41..42] -RRB-)
        (CD:[42..45] :61) (HYPH:[45..46] -) (CD:[46..48] 7.)))

;sentence 1 Span:54..194
;The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of 
;testosterone and benzphetamine in human adult and fetal liver.
;[66..103]:cyp450:"cytochrome P450 3A (CYP3A) isoform(s)"
;[132..144]:substance:"testosterone"
;[149..162]:substance:"benzphetamine"
(SENT
  (NP-HLN
    (NP (DT:[54..57] The) (NN:[58..62] role))
    (PP (IN:[63..65] of)
      (NP
        (NML
          (NML (NN:[66..76] cytochrome) (NN:[77..81] P450) (NN:[82..84] 3A))
          (NML (-LRB-:[85..86] -LRB-) (NN:[86..91] CYP3A) (-RRB-:[91..92] -RRB-)))
        (NN:[93..103] isoform-LRB-s-RRB-)))
    (PP (IN:[104..106] in)
      (NP
        (NP (JJ:[107..116] oxidative) (NN:[117..127] metabolism))
        (PP (IN:[128..130] of)
          (NP (NN:[132..144] testosterone) (CC:[145..148] and)
              (NN:[149..162] benzphetamine)))))
    (PP-LOC (IN:[163..165] in)
      (NP
        (NP
          (ADJP-2 (JJ:[166..171] human))
          (JJ:[172..177] adult)
          (NML-1 (-NONE-:[177..177] *P*)))
        (CC:[178..181] and)
        (NP
          (ADJP-2 (-NONE-:[181..181] *P*))
          (JJ:[182..187] fetal)
          (NML-1 (NN:[188..193] liver)))))
    (.:[193..194] .)))

;section 2 Span:198..240
;Maenpaa J, Pelkonen O, Cresteil T, Rane A.
(SEC
  (FRAG (NNP:[198..205] Maenpaa) (NNP:[206..208] J,) (NNP:[209..217] Pelkonen)
        (NNP:[218..219] O) (VBD:[219..220] ,) (NNP:[221..229] Cresteil)
        (NNP:[230..231] T) (,:[231..232] ,) (NNP:[233..237] Rane)
        (NN:[238..240] A.)))

;section 3 Span:244..318
;Department of Clinical Pharmacology, Akademiska Hospital, Uppsala, Sweden.
(SEC
  (FRAG (NNP:[244..254] Department) (IN:[255..257] of) (NNP:[258..266] Clinical)
        (NNP:[267..279] Pharmacology) (,:[279..280] ,)
        (NNP:[281..291] Akademiska) (NNP:[292..300] Hospital) (,:[300..301] ,)
        (NNP:[302..309] Uppsala) (,:[309..310] ,) (NNP:[311..317] Sweden)
        (.:[317..318] .)))

;sentence 4 Span:322..400
;Testosterone metabolism was studied in human adult and fetal liver
;microsomes.
;[322..334]:substance:"Testosterone"
(SENT
  (S
    (NP-SBJ-3 (NN:[322..334] Testosterone) (NN:[335..345] metabolism))
    (VP (VBD:[346..349] was)
      (VP (VBN:[350..357] studied)
        (NP-3 (-NONE-:[357..357] *))
        (PP-LOC (IN:[358..360] in)
          (NP
            (NP
              (ADJP-1 (JJ:[361..366] human))
              (JJ:[367..372] adult)
              (NML-2 (-NONE-:[372..372] *P*)))
            (CC:[373..376] and)
            (NP
              (ADJP-1 (-NONE-:[376..376] *P*))
              (JJ:[377..382] fetal)
              (NML-2 (NN:[383..388] liver) (NNS:[389..399] microsomes)))))))
    (.:[399..400] .)))

;sentence 5 Span:402..574
;In fetal livers 6 beta-hydroxylase (6 beta OH) activity (1-2% of adult
;activity)  and 2 alpha-hydroxylase (2 alpha OH) activity (about 40% of adult
;activity) were  present.
;[418..436]:substance:"6 beta-hydroxylase"
;[438..447]:substance:"6 beta OH"
;[459..463]:quantitative-value:"1-2%"
;[488..507]:substance:"2 alpha-hydroxylase"
;[509..519]:substance:"2 alpha OH"
;[537..540]:quantitative-value:"40%"
(SENT
  (S
    (PP-LOC (IN:[402..404] In)
      (NP (JJ:[405..410] fetal) (NNS:[411..417] livers)))
    (NP-SBJ
      (NP
        (NP
          (NML
            (NML (CD:[418..419] 6) (NN:[420..436] beta-hydroxylase))
            (NP (-LRB-:[437..438] -LRB-)
               (CD:[438..439] 6) (SYM:[440..444] beta) (NN:[445..447] OH)
              (-RRB-:[447..448] -RRB-)))
          (NN:[449..457] activity))
        (PRN (-LRB-:[458..459] -LRB-)
          (NP
            (NP
              (QP (CD:[459..460] 1) (HYPH:[460..461] -) (CD:[461..462] 2))
              (NN:[462..463] %))
            (PP (IN:[464..466] of)
              (NP (JJ:[467..472] adult) (NN:[473..481] activity))))
          (-RRB-:[481..482] -RRB-)))
      (CC:[484..487] and)
      (NP
        (NP
          (NML
            (NML (CD:[488..489] 2) (NN:[490..507] alpha-hydroxylase))
            (NML (-LRB-:[508..509] -LRB-)
               (CD:[509..510] 2) (SYM:[511..516] alpha) (NN:[517..519] OH)
              (-RRB-:[519..520] -RRB-)))
          (NN:[521..529] activity))
        (PRN (-LRB-:[530..531] -LRB-)
          (NP
            (NP
              (QP (RB:[531..536] about) (CD:[537..539] 40))
              (NN:[539..540] %))
            (PP (IN:[541..543] of)
              (NP (JJ:[544..549] adult) (NN:[550..558] activity))))
          (-RRB-:[558..559] -RRB-))))
    (VP (VBD:[560..564] were)
      (ADJP-PRD (JJ:[566..573] present)))
    (.:[573..574] .)))

;sentence 6 Span:575..631
;Also some fetal livers produced two unknown metabolites.
;[619..630]:substance:"metabolites"
(SENT
  (S
    (ADVP (RB:[575..579] Also))
    (NP-SBJ (DT:[580..584] some) (JJ:[585..590] fetal) (NNS:[591..597] livers))
    (VP (VBD:[598..606] produced)
      (NP (CD:[607..610] two) (JJ:[611..618] unknown)
          (NNS:[619..630] metabolites)))
    (.:[630..631] .)))

;sentence 7 Span:633..716
;Androstenedione was formed in all fetal livers studied (10-20% of adult 
;activity).
;[633..648]:substance:"Androstenedione"
;[689..695]:quantitative-value:"10-20%"
(SENT
  (S
    (NP-SBJ-1 (NN:[633..648] Androstenedione))
    (VP (VBD:[649..652] was)
      (VP (VBN:[653..659] formed)
        (NP-1 (-NONE-:[659..659] *))
        (PP-LOC (IN:[660..662] in)
          (NP
            (NP (DT:[663..666] all) (JJ:[667..672] fetal)
                (NNS:[673..679] livers))
            (VP (VBN:[680..687] studied)
              (NP (-NONE-:[687..687] *)))))
        (PRN (-LRB-:[688..689] -LRB-)
          (NP
            (NP
              (QP (CD:[689..691] 10) (HYPH:[691..692] -) (CD:[692..694] 20))
              (NN:[694..695] %))
            (PP (IN:[696..698] of)
              (NP (JJ:[699..704] adult) (NN:[706..714] activity))))
          (-RRB-:[714..715] -RRB-))))
    (.:[715..716] .)))

;sentence 8 Span:717..963
;Testosterone hydroxylations at 6 beta-, 2 beta-, 15 alpha- and 15 
;beta-positions were associated with CYP3A isoform(s) in adult liver, because 
;they were strongly inhibited by midazolam, a known substrate for CYP3A4 and
;by  anti-CYP3A4 antibody.
;[717..729]:substance:"Testosterone"
;[820..836]:cyp450:"CYP3A isoform(s)"
;[894..903]:substance:"midazolam"
;[913..922]:substance:"substrate"
;[927..933]:cyp450:"CYP3A4"
;[947..953]:cyp450:"CYP3A4"
;[954..962]:substance:"antibody"
(SENT
  (S
    (NP-SBJ-3
      (NP (NN:[717..729] Testosterone) (NNS:[730..744] hydroxylations))
      (PP-LOC (IN:[745..747] at)
        (NP
          (NP
            (NML (CD:[748..749] 6) (SYM:[750..754] beta))
            (HYPH:[754..755] -)
            (NML-2 (-NONE-:[755..755] *P*)))
          (,:[755..756] ,)
          (NP
            (NML (CD:[757..758] 2) (SYM:[759..763] beta))
            (HYPH:[763..764] -)
            (NML-2 (-NONE-:[764..764] *P*)))
          (,:[764..765] ,)
          (NP
            (NML (CD:[766..768] 15) (SYM:[769..774] alpha))
            (HYPH:[774..775] -)
            (NML-2 (-NONE-:[775..775] *P*)))
          (CC:[776..779] and)
          (NP
            (NML (CD:[780..782] 15) (SYM:[784..788] beta))
            (HYPH:[788..789] -)
            (NML-2 (NNS:[789..798] positions))))))
    (VP (VBD:[799..803] were)
      (VP (VBN:[804..814] associated)
        (NP-3 (-NONE-:[814..814] *))
        (PP-CLR (IN:[815..819] with)
          (NP (NN:[820..825] CYP3A) (NN:[826..836] isoform-LRB-s-RRB-)))
        (PP-LOC (IN:[837..839] in)
          (NP (JJ:[840..845] adult) (NN:[846..851] liver)))
        (,:[851..852] ,)
        (SBAR-PRP (IN:[853..860] because)
          (S
            (NP-SBJ-1 (PRP:[862..866] they))
            (VP (VBD:[867..871] were)
              (ADVP (RB:[872..880] strongly))
              (VP (VBN:[881..890] inhibited)
                (NP-1 (-NONE-:[890..890] *))
                (PP
                  (PP (IN:[891..893] by)
                    (NP-LGS
                      (NP (NN:[894..903] midazolam))
                      (,:[903..904] ,)
                      (NP
                        (NP (DT:[905..906] a) (VBN:[907..912] known)
                            (NN:[913..922] substrate))
                        (PP (IN:[923..926] for)
                          (NP (NN:[927..933] CYP3A4))))))
                  (CC:[934..937] and)
                  (PP (IN:[938..940] by)
                    (NP-LGS
                      (NML (AFX:[942..946] anti) (HYPH:[946..947] -)
                           (NN:[947..953] CYP3A4))
                      (NN:[954..962] antibody))))))))))
    (.:[962..963] .)))

;sentence 9 Span:964..1057
;Fetal liver activities were consistently inhibited less  than the activities
;in adult livers.
(SENT
  (S
    (NP-SBJ-1 (JJ:[964..969] Fetal) (NN:[970..975] liver)
              (NNS:[976..986] activities))
    (VP (VBD:[987..991] were)
      (ADVP (RB:[992..1004] consistently))
      (VP (VBD:[1005..1014] inhibited)
        (NP-1 (-NONE-:[1014..1014] *))
        (ADVP (RBR:[1015..1019] less)
          (PP (IN:[1021..1025] than)
            (NP
              (NP (DT:[1026..1029] the) (NNS:[1030..1040] activities))
              (PP-LOC (IN:[1041..1043] in)
                (NP (JJ:[1044..1049] adult) (NNS:[1050..1056] livers))))))))
    (.:[1056..1057] .)))

;sentence 10 Span:1058..1164
;The formation of androstenedione was not  affected by these inhibitors in
;fetal or adult liver microsomes.
;[1075..1090]:substance:"androstenedione"
;[1118..1128]:substance:"inhibitors"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1058..1061] The) (NN:[1062..1071] formation))
      (PP (IN:[1072..1074] of)
        (NP (NN:[1075..1090] androstenedione))))
    (VP (VBD:[1091..1094] was) (RB:[1095..1098] not)
      (VP (VBN:[1100..1108] affected)
        (NP-2 (-NONE-:[1108..1108] *))
        (PP (IN:[1109..1111] by)
          (NP-LGS (DT:[1112..1117] these) (NNS:[1118..1128] inhibitors)))
        (PP-LOC (IN:[1129..1131] in)
          (NP
            (NP (JJ:[1132..1137] fetal)
              (NML-1 (-NONE-:[1137..1137] *P*)))
            (CC:[1138..1140] or)
            (NP (JJ:[1141..1146] adult)
              (NML-1 (NN:[1147..1152] liver) (NNS:[1153..1163] microsomes)))))))
    (.:[1163..1164] .)))

;sentence 11 Span:1165..1255
;Benzphetamine  N-demethylase activity in the fetal livers was about 40% of
;adult activity.
;[1165..1193]:substance:"Benzphetamine  N-demethylase"
;[1233..1236]:quantitative-value:"40%"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (NN:[1165..1178] Benzphetamine) (NN:[1180..1193] N-demethylase))
        (NN:[1194..1202] activity))
      (PP-LOC (IN:[1203..1205] in)
        (NP (DT:[1206..1209] the) (JJ:[1210..1215] fetal)
            (NNS:[1216..1222] livers))))
    (VP (VBD:[1223..1226] was)
      (NP-PRD
        (NP
          (QP (RB:[1227..1232] about) (CD:[1233..1235] 40))
          (NN:[1235..1236] %))
        (PP (IN:[1237..1239] of)
          (NP (JJ:[1240..1245] adult) (NN:[1246..1254] activity)))))
    (.:[1254..1255] .)))

;sentence 12 Span:1257..1491
;Anti-CYP3A4 antibody had no effect on that activity in fetal or in adult
;liver  microsomes, whereas a monoclonal antibody 1-68-11 (generated against
;rat  CYP2C11) slightly inhibited benzphetamine N-demethylase activity in
;adult liver.
;[1257..1277]:substance:"Anti-CYP3A4 antibody"
;[1359..1386]:substance:"monoclonal antibody 1-68-11"
;[1411..1418]:cyp450:"CYP2C11"
;[1439..1466]:substance:"benzphetamine N-demethylase"
(SENT
  (S
    (NP-SBJ
      (NML (AFX:[1257..1261] Anti) (HYPH:[1261..1262] -)
           (NN:[1262..1268] CYP3A4))
      (NN:[1269..1277] antibody))
    (VP (VBD:[1278..1281] had)
      (NP
        (NP (DT:[1282..1284] no) (NN:[1285..1291] effect))
        (PP (IN:[1292..1294] on)
          (NP (DT:[1295..1299] that) (NN:[1300..1308] activity))))
      (PP-LOC
        (PP (IN:[1309..1311] in)
          (NP (JJ:[1312..1317] fetal)
            (NML-1 (-NONE-:[1317..1317] *RNR*))))
        (NN:[1318..1320] or)
        (PP (IN:[1321..1323] in)
          (NP (JJ:[1324..1329] adult)
            (NML-1 (-NONE-:[1329..1329] *RNR*))))
        (NML-1 (NN:[1330..1335] liver) (NNS:[1337..1347] microsomes))))
    (,:[1347..1348] ,)
    (SBAR-ADV (IN:[1349..1356] whereas)
      (S
        (NP-SBJ
          (NP
            (NP (DT:[1357..1358] a) (JJ:[1359..1369] monoclonal)
                (NN:[1370..1378] antibody))
            (NP (NN:[1379..1386] 1-68-11)))
          (PRN (-LRB-:[1387..1388] -LRB-)
            (VP (VBN:[1388..1397] generated)
              (NP (-NONE-:[1397..1397] *))
              (PP (IN:[1398..1405] against)
                (NP (JJ:[1406..1409] rat) (NN:[1411..1418] CYP2C11))))
            (-RRB-:[1418..1419] -RRB-)))
        (ADVP (RB:[1420..1428] slightly))
        (VP (VBD:[1429..1438] inhibited)
          (NP
            (NML (NN:[1439..1452] benzphetamine) (NN:[1453..1466] N-demethylase))
            (NN:[1467..1475] activity))
          (PP-LOC (IN:[1476..1478] in)
            (NP (JJ:[1479..1484] adult) (NN:[1485..1490] liver))))))
    (.:[1490..1491] .)))

;sentence 13 Span:1493..1604
;This study indicates that human fetal and adult liver are dissimilar in their
; testosterone metabolism pattern.
;[1572..1584]:substance:"testosterone"
(SENT
  (S
    (NP-SBJ (DT:[1493..1497] This) (NN:[1498..1503] study))
    (VP (VBZ:[1504..1513] indicates)
      (SBAR (IN:[1514..1518] that)
        (S
          (NP-SBJ
            (NP
              (ADJP-2 (JJ:[1519..1524] human))
              (JJ:[1525..1530] fetal)
              (NML-1 (-NONE-:[1530..1530] *P*)))
            (CC:[1531..1534] and)
            (NP
              (ADJP-2 (-NONE-:[1534..1534] *P*))
              (JJ:[1535..1540] adult)
              (NML-1 (NN:[1541..1546] liver))))
          (VP (VBP:[1547..1550] are)
            (ADJP-PRD (JJ:[1551..1561] dissimilar))
            (PP (IN:[1562..1564] in)
              (NP (PRP$:[1565..1570] their)
                (NML (NN:[1572..1584] testosterone) (NN:[1585..1595] metabolism))
                (NN:[1596..1603] pattern)))))))
    (.:[1603..1604] .)))

;sentence 14 Span:1605..1702
;The formation of androstenedione from  testosterone in fetal liver may have a
;physiological role.
;[1622..1637]:substance:"androstenedione"
;[1644..1656]:substance:"testosterone"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1605..1608] The) (NN:[1609..1618] formation))
      (PP (IN:[1619..1621] of)
        (NP (NN:[1622..1637] androstenedione)))
      (PP (IN:[1638..1642] from)
        (NP (NN:[1644..1656] testosterone)))
      (PP-LOC (IN:[1657..1659] in)
        (NP (JJ:[1660..1665] fetal) (NN:[1666..1671] liver))))
    (VP (MD:[1672..1675] may)
      (VP (VB:[1676..1680] have)
        (NP (DT:[1681..1682] a) (JJ:[1683..1696] physiological)
            (NN:[1697..1701] role))))
    (.:[1701..1702] .)))

;sentence 15 Span:1703..1831
;Testosterone  hydroxylases are less inhibited by anti-CYP3A4 antibody,
;midazolam and  progesterone in fetal than in adult liver.
;[1703..1715]:substance:"Testosterone"
;[1717..1729]:substance:"hydroxylases"
;[1752..1772]:substance:"anti-CYP3A4 antibody"
;[1774..1783]:substance:"midazolam"
;[1789..1801]:substance:"progesterone"
(SENT
  (S
    (NP-SBJ-2 (NN:[1703..1715] Testosterone) (NNS:[1717..1729] hydroxylases))
    (VP (VBP:[1730..1733] are)
      (ADVP
        (ADVP (RBR:[1734..1738] less))
        (PP-1 (-NONE-:[1738..1738] *ICH*)))
      (VP (VBN:[1739..1748] inhibited)
        (NP-2 (-NONE-:[1748..1748] *))
        (PP (IN:[1749..1751] by)
          (NP-LGS
            (NP
              (NML (AFX:[1752..1756] anti) (HYPH:[1756..1757] -)
                   (NN:[1757..1763] CYP3A4))
              (NN:[1764..1772] antibody))
            (,:[1772..1773] ,)
            (NP (NN:[1774..1783] midazolam))
            (CC:[1784..1787] and)
            (NP (NN:[1789..1801] progesterone))))
        (PP-LOC (IN:[1802..1804] in)
          (NP (JJ:[1805..1810] fetal)
            (NML-3 (-NONE-:[1810..1810] *RNR*))))
        (PP-1 (IN:[1811..1815] than)
          (PP-LOC (IN:[1816..1818] in)
            (NP (JJ:[1819..1824] adult)
              (NML-3 (-NONE-:[1824..1824] *RNR*)))))
        (NML-3 (NN:[1825..1830] liver))))
    (.:[1830..1831] .)))

;section 16 Span:1835..1879
;PMID: 8424894 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1835..1839] PMID) (::[1839..1840] :) (CD:[1841..1848] 8424894)
        (IN:[1849..1850] -LSB-) (NNP:[1850..1856] PubMed) (HYPH:[1857..1858] -)
        (JJ:[1859..1866] indexed) (IN:[1867..1870] for)
        (NNP:[1871..1879] MEDLINE-RSB-)))
